date,title,source
Nov-12-18,Cellectar Announces FDA Grants Exemption to Import Alert for CLR 131 Hematology Studies,GlobeNewswire
Nov-13-18,Cellectar Reports Third Quarter 2018 Financial Results and Provides Business Update,GlobeNewswire
Nov-21-18,Analysts Take Action on Health Care Stocks,GuruFocus.com
Dec-04-18,Cellectar Initiates Cohort 6 of Phase 1b Trial Evaluating CLR 131 in Relapsed/Refractory Multiple Myeloma,GlobeNewswire
Dec-11-18,Cellectar Granted Japanese Patent for CLR 131,GlobeNewswire
Jan-03-19,Cellectar Biosciences to Present at the Biotech Showcase,GlobeNewswire
Jan-07-19,Cellectar Provides Update on Phase 1 Trial of CLR 131 in Relapsed/Refractory Multiple Myeloma,GlobeNewswire
Jan-22-19,"What Kind Of Shareholders Own Cellectar Biosciences, Inc. (NASDAQ:CLRB)?",Simply Wall St.
Jan-23-19,"Cellectar Biosciences to Present at NobleConXV, Noble Capital Markets Fifteenth Annual Investor Conference",GlobeNewswire
Feb-05-19,Cellectar Biosciences to Present at the Annual BIO CEO & Investor Conference,GlobeNewswire
Feb-25-19,Cellectar Reports Positive Top-line Response Rate of 30% from R/R Multiple Myeloma Cohort in Ongoing Phase 2 Study of CLR 131,GlobeNewswire
Feb-26-19,"Cellectar Reports Financial Results for Year Ended December 31, 2018 and Provides a Corporate Update",GlobeNewswire
Mar-19-19,FDA Grants Exemption to Import Alert for Cellectars CLR 131 in Pediatric and Adolescent Patients,GlobeNewswire
